>

MEETINGS / EVENTS

RSS

November 08 - 09 2014, 12:00 AM - 12:00 AM

ASA Quality Meeting 2014

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

>

FDA MEDWATCH ALERTS

October 20, 2014

Lidocaine HCI Injection, USP 10 MG Per ML, 30 ML Single-Dose, Preservative-Free, by Hospira: Recall - Particulate Matter

Summary:

FDA Medwatch Alert 10-20-14

October 16, 2014

FDA MedWatch - LifeCare Flexible Intravenous Solutions by Hospira, Inc.: Recall - Potential for Leakage

Summary:

FDA MedWatch LifeCare Flexible Intravenous Solutions by Hospira Inc

October 13, 2014

FDA MedWatch - CareFusion EnVe and ReVel Ventilators: Class 1 Recall - Power Connection Failure

Summary:

FDA MedWatch CareFusion EnVe and ReVel Ventilators

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

ASA Testifies Before FDA on Safe Use of Propofol

ASA Immediate Past President Eugene P. Sinclair, M.D. testified before the FDA Advisory Committee on Anesthetic and Life Support Drugs on November 10, 2005. At issue was the petition filed by the American College of Gastroenterology to remove from the propofol (Diprivan®) labeling the following language:

“For general anesthesia or monitored anesthesia care (MAC) sedation, DIPRIVAN Injectable Emulsion should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the surgical/diagnostic procedure.”

Dr. Sinclair was followed at the podium by anesthesiologists Carol Rose, M.D., of the University of Pittsburgh Medical Center, and until recently a member of the Advisory Committee, and Marc Koch, M.D., M.B.A., President and Chief Executive Officer of Somnia, Inc., a New York based Anesthesia Management Company, which specializes in providing comprehensive anesthesia, pain management and accreditation consulting services to office-based surgical facilities and ambulatory surgery centers throughout the United States. These three anesthesiologists were the only witnesses and they each testified in favor of keeping the warning on the propofol labeling.

Download a copy of Dr. Sinclair’s testimony and ASA’s letter commenting on the ACG petition filed with the FDA on October 19.